Sientra (SIEN) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Sientra (SIEN) Misses Q4 EPS Views
March 9, 2016 4:08 PM EST
Highlights
Efficacy supported by extensive clinical studiesCurrently used by over 1,800 physiciansComplements current portfolio with targeted solution for plastic surgeonsLeverages existing Sientra sales force to grow revenues and brand
SANTA BARBARA, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (Sientra or the Company), a medical aesthetics company, today announced the acquisition from Enaltus, LLC of the exclusive U.S. rights to bioCorneum®, an advanced silicone gel scar management products, for $7.0 million... More
March 9, 2016 4:04 PM EST
Highlights
Independent third-party testing and analysis concludes Sientra implants continue to be safe choice for surgeons and patientsSales of FDA-approved product portfolio has been initiated as of March 1stAcquires bioCorneum® advanced silicone gel scar management therapy for $7.0 million$112.8 million cash and cash equivalents as of December 31, 2015
SANTA BARBARA, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (Sientra or the Company), a medical aesthetics company, today announced... More
